Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Gammaglobulin (IVIg) Treatment Report
What is Gammaglobulin (IVIg)?

Intravenous gammaglobulin, or immune globulin (IVIg) has been used in the treatment of various autoimmune diseases and in relapsing-remitting MS. Studies report a reduction in the number and severity of acute exacerbations and resulted in a lesser neurological disability. Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell
# of patients evaluated by
Multiple Sclerosis MS 5 1
Relapse MS (exacerbation) 2 1
General health 1 0
Support another treatment 1 1

See all 6 patients currently taking Gammaglobulin (IVIg)

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
2 67%
None
1 33%

Dosages

  35 g monthly 40 mg monthly 45 g monthly 200 mg monthly 40 L daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Gammaglobulin (IVIg) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended
2 50% Course of treatment ended: 50%
Did not seem to work
1 25% Did not seem to work: 25%
Doctor's advice
1 25% Doctor's advice: 25%

See all 4 patients who’ve stopped taking Gammaglobulin (IVIg)

Currently Taking Gammaglobulin (IVIg)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Gammaglobulin (IVIg)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 67%
Usually
0 0%
Sometimes
0 0%
Never
1 33%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
2 67%
A little
0 0%
Not at all
1 33%

Cost

Paid out of pocket

$200+
1 33%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

Report created on March 19, 2010.